Bortezomib-Cyclophosphamide-Dexamethasone (VCD)versusBortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis-Reference-Cited by-同舟云学术

Bortezomib-Cyclophosphamide-Dexamethasone (VCD)versusBortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis

Published:2014-05-26 Issue:5 Volume:166 Page:702-710
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Leiba Merav¹,Kedmi Meirav¹,Duek Adrian¹,Freidman Tzachi¹,Weiss Mia²,Leiba Ronit³,Nagler Arnon¹,Avigdor Abraham¹

Affiliation:

1. Division of Haematology and Bone marrow Transplantation; Sheba Medical Centre; Tel-Hashomer and Sackler School of Medicine; Tel Aviv University; Tel Aviv Israel

2. Arrow project; Sheba Medical Centre; Tel-Hashomer and Sackler School of Medicine; Tel Aviv University; Tel Aviv Israel

3. Biostatistics; Haifa Israel

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12946/fullpdf

Reference37 articles.

1. The revised CONSORT statement for reporting randomized trials: explanation and elaboration;Altman;Annals of Internal Medicine,2001

2. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature;Argyriou;Blood,2008

3. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma;Bensinger;British Journal of Haematology,2009